Letrozole
Product Images NDC 42254-243

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 42254-243). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sturctural Formula Of Letrozole (0193faa4 9b02 4ccd 9751 De6124cc8c68 01)

Chemical structure of letrozole, showing the molecular arrangement of its atoms including two nitrile groups attached to aromatic rings and a triazole ring as part of the molecule.*

FDA Label Image

Figure 1. Disease-free Survival (median Follow-up 73 Months, Itt Approach) (0193faa4 9b02 4ccd 9751 De6124cc8c68 02)

Kaplan-Meier survival curve comparing Letrozole and Tamoxifen treatments over 72 months. The graph shows survival probability (Y-axis) versus months (X-axis), with two lines representing Letrozole and Tamoxifen groups. The chart includes patient numbers at risk, events, and censored data for each treatment group.*

FDA Label Image

Figure 2 Kaplan-meier Esitmates Of Time To Progression (tamoxifen Study) (0193faa4 9b02 4ccd 9751 De6124cc8c68 03)

A progression-free survival curve comparing Letrozole 2.5 mg and Tamoxifen 20 mg over time in months. The y-axis shows progression-free probability, and the x-axis shows months, with Letrozole represented by a solid line and Tamoxifen by a dashed line.*

FDA Label Image

Figure 3 Survival By Randomized Treatment Arm (0193faa4 9b02 4ccd 9751 De6124cc8c68 04)

A survival curve chart comparing patient survival over time in months for Letrozole first versus Tamoxifen first treatment groups. The y-axis shows the proportion alive from 0 to 1.0, and the x-axis shows time in months from 0 to 60. Two lines depict survival trends for Letrozole (solid line) and Tamoxifen (dashed line) over the study period.*

FDA Label Image

Figure 4. Kaplan-meier Estimates Of Time To Progression (megestrol Acetate Study) (0193faa4 9b02 4ccd 9751 De6124cc8c68 05)

A survival curve chart showing time to progression in days on the x-axis and proportion on the y-axis. The chart compares progression over time among different treatment groups including Letrozole 0.5 mg, Letrozole 2.5 mg, and MA, with corresponding survival curves displayed as lines.*

FDA Label Image

Figure 5 Kaplan-meier Estimates Of Time To Progression (aminoglutethimide Study) (0193faa4 9b02 4ccd 9751 De6124cc8c68 06)

A Kaplan-Meier survival curve comparing time to progression in days among three treatment groups: Letrozole 0.5 mg, Letrozole 2.5 mg, and AG (control). The graph displays the proportion of patients without progression over time for each group, with Letrozole dosages represented by distinct line styles.*

FDA Label Image

Letrozole 2.5mg (0193faa4 9b02 4ccd 9751 De6124cc8c68 07)

Letrozole 2.5mg tablets packaging label by Rebel Distributors Corp, containing 30 tablets. Each tablet contains 2.5mg of Letrozole, USP. The label includes instructions on tablet appearance and storage conditions, and states the manufacturer as Teva Pharmaceutical Industries Ltd., Jerusalem, Israel.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.